Levicept Taps Biotech Finance Veteran as CFO Amid LEVI-04 Development Push
Event summary
- Darlene Deptula-Hicks appointed CFO of Levicept, replacing Nicholas Stern.
- Deptula-Hicks brings experience in $85M follow-on public offering and all-cash sale of F-star Therapeutics.
- Levicept's LEVI-04 completed Phase II trial with over 500 patients, showing pain relief and potential disease modification.
The big picture
Levicept's appointment of a seasoned biotech CFO underscores its push toward late-stage development for LEVI-04, a potential first-in-class treatment for osteoarthritis. The move comes as the company capitalizes on positive Phase II data, positioning itself in a competitive market where non-opioid pain therapies are increasingly sought after. Deptula-Hicks' track record in successful financings and exits suggests Levicept may be preparing for significant capital raises or strategic transactions.
What we're watching
- Capital Strategy
- How Deptula-Hicks' M&A and fundraising experience will shape Levicept's next financing moves.
- Clinical Milestones
- The pace at which LEVI-04 advances toward late-stage development following Phase II results.
- Market Positioning
- Whether Levicept can leverage Deptula-Hicks' network to secure strategic partnerships in the $10B osteoarthritis market.
Related topics